Ipamorelin Dosage: Protocol, Timing & Stacking Guide

Overview

Ipamorelin is a selective growth hormone releasing peptide (GHRP) that stimulates GH secretion through the ghrelin/GHS-R1a receptor. Unlike older GHRPs such as GHRP-6 and GHRP-2, ipamorelin produces minimal effects on cortisol, prolactin, and appetite at standard doses, making it one of the cleanest GH secretagogues available. Its selectivity for GH release without significant activation of other hormonal pathways is the primary reason ipamorelin has become the most widely used GHRP in clinical peptide therapy. This guide covers evidence-based dosing protocols, meal timing interactions, stacking with CJC-1295, and practical considerations for cycle management.

Standard Dosing: 200-300 mcg Per Injection

The standard ipamorelin dose range of 200-300 mcg per injection is derived from dose-response studies conducted during clinical development. Raun et al. (1998) demonstrated that ipamorelin produces a dose-dependent increase in GH release in swine models, with the dose-response curve showing a clear plateau at higher doses where additional compound does not produce proportionally greater GH output. Human clinical trials by Gobburu et al. (1999) established the pharmacokinetic and pharmacodynamic profile, showing that subcutaneous doses in the 1-3 mcg/kg range (approximately 70-210 mcg for a 70 kg adult) produced robust GH pulses with peak levels occurring approximately 30-40 minutes post-injection. The 200-300 mcg range that has become standard practice represents the sweet spot where GH release is near-maximal but cortisol and prolactin remain unaffected. At doses above 300 mcg per injection, some studies observe the beginning of cortisol elevation, which undermines one of ipamorelin's key advantages over less selective GHRPs. Clinical peptide therapy practices typically prescribe 200 mcg for individuals under 80 kg and 300 mcg for those over 80 kg, though the pharmacological basis for this weight-based adjustment is not firmly established — the dose-response plateau means that the difference between 200 mcg and 300 mcg in terms of GH output is relatively small for most individuals. Starting at 200 mcg is the conservative and commonly recommended approach, with the option to increase to 300 mcg if the GH response (assessed via IGF-1 blood testing at 4-6 weeks) is below expectations.

Injection Frequency and Timing Around Meals

Ipamorelin's short half-life (approximately 2 hours) necessitates multiple daily injections to achieve sustained GH elevation throughout the day. The most common protocols use 2-3 injections daily, spaced throughout waking hours. A three-times-daily protocol (morning, afternoon, pre-bed) is considered optimal for maximizing cumulative daily GH output, while twice-daily protocols (morning and pre-bed) offer a practical compromise for users who cannot inject mid-day. Meal timing is critically important with ipamorelin and all GH secretagogues. Food intake — particularly carbohydrates and fats — triggers an insulin response that directly suppresses GH release. Somatostatin, the GH-inhibiting hormone, is also elevated in the postprandial state. Clinical guidance recommends injecting ipamorelin at least 30 minutes before eating or at least 2 hours after a meal. The pre-bed injection should follow at least 2 hours of fasting to align with the natural nocturnal GH surge. The practical three-times-daily schedule works as follows: first injection upon waking (30 minutes before breakfast), second injection in the mid-afternoon (at least 2 hours after lunch), and third injection 30-60 minutes before bed (at least 2 hours after dinner). Some users find that the afternoon injection is the most logistically challenging, which is why twice-daily protocols (waking and pre-bed) remain popular despite slightly lower total daily GH output. Protein intake appears to have less suppressive effect on GH release than carbohydrates or fats, though complete fasting before injection is preferred when possible.

• Morning: Inject 200-300 mcg upon waking, 30 minutes before breakfast
• Afternoon (optional): Inject 200-300 mcg at least 2 hours after lunch
• Pre-bed: Inject 200-300 mcg at least 2 hours after dinner, 30-60 minutes before sleep
• Total daily dose: 400-900 mcg depending on 2x or 3x daily protocol
• Fasting window: Minimum 30 min before eating; 2 hours after eating

CJC-1295 Stacking: The Gold Standard Protocol

The combination of ipamorelin with CJC-1295 (either with DAC or without DAC, also called modified GRF 1-29) is the most widely prescribed peptide stack in clinical growth hormone optimization practice. This combination leverages complementary mechanisms: ipamorelin amplifies GH pulse amplitude via the ghrelin receptor, while CJC-1295 increases GH pulse frequency via the GHRH receptor. The synergistic effect produces significantly greater total GH output than either peptide alone. The standard stacking protocol uses ipamorelin 200-300 mcg combined with modified GRF 1-29 (CJC-1295 without DAC) at 100-200 mcg, injected simultaneously from the same syringe 2-3 times daily. Both peptides are reconstituted separately, then the appropriate volumes are drawn into a single insulin syringe and injected subcutaneously. The same meal-timing rules apply to the stack — inject on an empty stomach. For CJC-1295 with DAC (drug affinity complex), the protocol differs because the DAC modification extends the half-life to approximately 8 days. In this case, CJC-1295 DAC is typically injected once or twice per week at 1-2 mg per injection, while ipamorelin continues at 200-300 mcg 2-3 times daily on injection days and non-injection days alike. The clinical rationale for the CJC-1295/ipamorelin stack extends beyond simple GH amplification. By activating both receptor pathways simultaneously, the stack more closely mimics the natural physiological regulation of GH release, which involves coordinated GHRH and ghrelin signaling. This dual-receptor activation pattern may explain why clinical practitioners report the stack produces more natural-feeling results — better sleep quality, improved recovery, gradual body composition changes — compared to higher-dose single-agent protocols.

• CJC-1295 no DAC (mod GRF 1-29): 100-200 mcg + ipamorelin 200-300 mcg, 2-3x daily
• CJC-1295 with DAC: 1-2 mg once or twice weekly + ipamorelin 200-300 mcg 2-3x daily
• Both peptides can be drawn into the same syringe for injection
• Same fasting requirements apply to the combination
• Synergistic GH output exceeds either peptide alone by approximately 2-3 fold

Reconstitution and Storage

Ipamorelin is supplied as a lyophilized (freeze-dried) white powder, typically in vials containing 2 mg or 5 mg. Proper reconstitution is essential for dosing accuracy and peptide stability. For a 5 mg vial, adding 2.5 mL of bacteriostatic water (BAW) yields a concentration of 2 mg/mL, or 2000 mcg/mL. At this concentration, a 200 mcg dose equals 0.1 mL (10 units on a U-100 insulin syringe), and a 300 mcg dose equals 0.15 mL (15 units). For a 2 mg vial, adding 1 mL of BAW yields the same 2 mg/mL concentration, with 200 mcg equal to 0.1 mL (10 units). These concentrations are commonly used because they produce practical injection volumes and straightforward dose calculations. Reconstitution technique matters for peptide integrity. Draw the appropriate volume of bacteriostatic water into an insulin syringe. Swab the vial stopper with alcohol. Insert the needle at an angle, aiming the stream of water down the inside wall of the vial rather than directly onto the lyophilized powder cake. Add the water slowly — rapid injection can damage the peptide structure. Do not shake the vial; instead, gently swirl or roll it between your palms until the powder is fully dissolved. The solution should be clear and colorless. Cloudiness, particulate matter, or discoloration indicates degradation — discard and do not use. After reconstitution, store the vial refrigerated at 2-8 degrees Celsius (36-46 degrees Fahrenheit). Protect from light. Reconstituted ipamorelin maintains stability for approximately 21-28 days when properly stored. Unreconstituted lyophilized powder should be stored frozen at minus 20 degrees Celsius for long-term stability, where it remains viable for 12-24 months.

• 5 mg vial + 2.5 mL BAW = 2 mg/mL (200 mcg = 10 units on U-100 syringe)
• 2 mg vial + 1 mL BAW = 2 mg/mL (200 mcg = 10 units on U-100 syringe)
• Inject water slowly down the vial wall; never shake
• Refrigerate after reconstitution; discard after 28 days
• Store unreconstituted powder frozen at -20°C for up to 24 months

Cycle Length and What to Expect

Standard ipamorelin cycles run 8-12 weeks, which provides sufficient time for IGF-1 levels to plateau and for body composition and recovery benefits to manifest. The timeline of expected effects follows a predictable pattern based on the pharmacology of GH secretion and downstream IGF-1 production. During the first 1-2 weeks, the most noticeable effect is improved sleep quality. Many users report deeper sleep, more vivid dreams, and feeling more rested upon waking. This occurs because the pre-bed injection amplifies the nocturnal GH surge, and GH has established effects on slow-wave (deep) sleep architecture. By weeks 2-4, users typically notice improved recovery from exercise — reduced soreness, faster resolution of minor injuries, and better tolerance of training volume. This corresponds to IGF-1 reaching its new elevated plateau, as the liver requires approximately 2-3 weeks of sustained GH stimulation to upregulate IGF-1 production maximally. Weeks 4-8 are when body composition changes become measurable — modest fat loss (particularly in the abdominal area) and improved skin quality (increased collagen synthesis) are commonly reported. Lean mass gains are modest with ipamorelin alone (approximately 1-3 lbs over a full cycle) because the GH elevation, while significant, is within physiological ranges rather than supraphysiological. By weeks 8-12, the cumulative effects on recovery, sleep, skin, and body composition are typically at their peak. Some users experience diminishing subjective improvements beyond week 12, though this may reflect adaptation to the new baseline rather than true receptor desensitization. After discontinuation, IGF-1 returns to baseline within 2-4 weeks. Like MK-677, ipamorelin does not suppress the gonadal axis and does not require post-cycle therapy.

Ipamorelin vs Other GHRPs: Why Dosing Differs

Understanding why ipamorelin's dosing differs from other growth hormone releasing peptides helps users appreciate its unique pharmacological profile and avoid the common mistake of applying dosing logic from one GHRP to another. GHRP-6, the oldest widely used GHRP, is typically dosed at 100-150 mcg per injection because it produces robust GH release at lower doses but also strongly stimulates appetite (through direct ghrelin mimicry) and elevates cortisol at doses above 100-150 mcg. GHRP-2 occupies a middle ground at 100-300 mcg per injection, producing stronger GH release per microgram than ipamorelin but with dose-dependent prolactin and cortisol elevation that limits the useful dose range. Hexarelin is the most potent GHRP by weight, effective at 50-100 mcg per injection, but causes significant cortisol and prolactin increases and demonstrates rapid receptor desensitization (loss of efficacy) within 4-8 weeks — a problem ipamorelin largely avoids. Ipamorelin's 200-300 mcg dose range reflects its lower potency per microgram relative to hexarelin and GHRP-2, but this is offset by its selectivity. The therapeutic window — the range between the minimally effective dose and the dose that produces unwanted effects — is substantially wider for ipamorelin than for any other GHRP. This means dosing errors (accidentally using slightly more or less than intended) have minimal consequences, and the margin of safety at the upper end of the dose range is more forgiving. Ipamorelin also shows less tendency toward tachyphylaxis (reduced response over time) compared to hexarelin, which is why ipamorelin cycles can run 12 weeks or longer while hexarelin protocols are typically limited to 4-8 weeks.

References

1. Ipamorelin, the first selective growth hormone secretagogue (1998) — PubMed
2. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (1999) — PubMed
3. Growth hormone releasing peptides: clinical and basic aspects (2000) — PubMed
4. Growth hormone secretagogues: history, mechanism of action, and clinical development (2005) — PubMed